HTX-019

HTX-019 is an IV injectable emulsion formulation designed to directly deliver aprepitant, the active ingredient in EMEND®️ capsules, which is the only Neurokinin 1 receptor antagonist (NK1 RA) to be approved in the United States, for the prevention of postoperative nausea and vomiting (PONV) in adults. The FDA-approved dosing for oral EMEND is 40 mg capsules within 3 hours prior to induction of anesthesia for surgery. In a Phase 1 clinical trial, HTX-019 32 mg as a 30-second IV injection was demonstrated to be bioequivalent to oral aprepitant 40 mg. The New Drug Application for HTX-019 is planned for the fourth quarter of 2021 for the prevention of PONV in adults.